Co-founded by MIT scientists in 2017 and headquartered in Cambridge, MA, Synlife's team is developing therapeutic and diagnostic platforms through bottom-up engineering of synthetic cells. While much of synthetic biology relies on top-down engineering of extant living systems, this strategy is constrained by the fundamental drives of biology, such as evolutionary pressures and resource utilization for the necessary functions of life. By building synthetic minimal cells bottom-up, Synlife can reconstitute desirable functions of biology.
Timeline
2018
Synlife raises a $700,000 seed round.
Funding rounds
Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
People
Name
Role
LinkedIn
Ed Boyden
Co-founder
Jeremy Wertheimer
Co-founder
Kate Adamala
Co-founder
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services